Tag: TTHX1114

San Diego, CA, December 1, 2021 – Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors have funded the third tranche of its $28 million Series A

Indianapolis, IN – March 10, 2021 – Price Vision Group announced today that it is the first site to initiate patient treatment in a clinical trial evaluating use of an experimental drug treatment in conjunction with a surgical procedure that

Study evaluating engineered FGF-1’s (TTHX114) potential in patients undergoing Descemet Stripping Only (DSO or DWEK) procedures San Diego, CA – February 9, 2021 – Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast

Trefoil provided an update on the company and its clinical program for TTHX1114 at the inaugural Eyecelerator 2020 virtual conference on November 6. TTHX1114 is the company’s first-in-class, engineered fibroblast growth factor 1 (FGF-1), for the regenerative treatment of corneal diseases. 

San Diego, CA – November 2, 2020 – Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference.  TTHX1114 is the company’s first-in-class, engineered fibroblast growth

Experienced clinical development executive to lead the TTHX1114 clinical study in corneal endothelial disease.